Intravesical Sodium Chondroitin Sulphate to Treat Overactive Bladder: Preliminary Result
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose: This study aimed to verify the efficacy and safety of intravesical treatment with sodium chondroitin sulfate (CS) in patients with overactive bladder (OAB) who are refractory to previous antimuscarinic treatment. Methods: This study was performed between June 2012 and January 2015 and included 31 consecutive women (mean age, 42.10±7.34 years) with OAB who had been previously treated with two types of antimuscarinic drugs. The results of gynecologic and cystoscopic examinations were normal, and OAB comorbidity was absent. Treatment with intravesical instillations containing 40 mL CS (0.2%; 2 mg/mL) was administered for 6 weeks; after weekly treatments, monthly treatments were administered. The OAB-validated 8 (OAB-V8) symptom scores, nocturia, frequency, urgency, urge incontinence, and urinary volumes measured by uroflowmetry were evaluated for all the patients. The values obtained before the treatment were statistically compared with those obtained six months after the treatment. Results: The duration of the symptoms was 18.36±6.19 months. A statistically significant improvement of the patients’ conditions was observed in terms of the OAB-V8 symptom scores, nocturia, frequency, urgency, urge incontinence, and urinary volumes measured by uroflowmetry after the treatment. Conclusions: Despite the limitations of this study, the outcomes confirmed that CS therapy is safe and effective for the treatment of OAB.
Abstract
Purpose: This study aimed to verify the efficacy and safety of intravesical treatment with sodium chondroitin sulfate (CS) in patients with overactive bladder (OAB) who are refractory to previous antimuscarinic treatment. Methods: This study was performed between June 2012 and January 2015 and included 31 consecutive women (mean age, 42.10±7.34 years) with OAB who had been previously treated with two types of antimuscarinic drugs. The results of gynecologic and cystoscopic examinations were normal, and OAB comorbidity was absent. Treatment with intravesical instillations containing 40 mL CS (0.2%; 2 mg/mL) was administered for 6 weeks; after weekly treatments, monthly treatments were administered. The OAB-validated 8 (OAB-V8) symptom scores, nocturia, frequency, urgency, urge incontinence, and urinary volumes measured by uroflowmetry were evaluated for all the patients. The values obtained before the treatment were statistically compared with those obtained six months after the treatment. Results: The duration of the symptoms was 18.36±6.19 months. A statistically significant improvement of the patients’ conditions was observed in terms of the OAB-V8 symptom scores, nocturia, frequency, urgency, urge incontinence, and urinary volumes measured by uroflowmetry after the treatment. Conclusions: Despite the limitations of this study, the outcomes confirmed that CS therapy is safe and effective for the treatment of OAB.
참고문헌 (22)
- Abrams P, "The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society", Neurourol Urodyn, 21, pp.167~178 (2002)
- Milsom I, "How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study", BJU Int, 87, pp.760~766 (2001)
- Stewart WF, "Prevalence and burden of overactive bladder in the United States", World J Urol, 20, pp.327~336 (2003)
- Yamanishi T, "Which muscarinic receptor is important in the bladder", World J Urol, 19, pp.299~306 (2001)
- Lapitan MC, "Asia-Pacific Continence Advisory Board. The epidemiology of overactive bladder among females in Asia: a questionnaire survey", Int Urogynecol J Pelvic Floor Dysfunct, 12, pp.226~231 (2001)
- Miller JJ, "Diagnosis and treatment of overactive bladder", Minerva Ginecol, 57, pp.501~520 (2005)
- Jayarajan J, "Pharmacotherapy of overactive bladder in adults: a review of efficacy, tolerability, and quality of life", Res Rep Urol, 6, pp.1~16 (2013)
- Gimbel H, "Lower urinary tract symptoms after total and subtotal hysterectomy: results of a randomized controlled trial", Int Urogynecol J Pelvic Floor Dysfunct, 16, pp.257~262 (2005)
- Curhan GC, "Stampfer MJ. Epidemiology of interstitial cystitis: a population based study", J Urol, 161, pp.549~552 (1999)
- Hanno PM, "The diagnosis of interstitial cystitis revisited: lessons learned from the National Institutes of Health Interstitial Cystitis Database study", J Urol, 161, pp.553~557 (1999)
- Chancellor MB, "Intravesical capsaicin and resiniferatoxin therapy: spicing up the ways to treat the overactive bladder", J Urol, 162, pp.3~11 (1999)
- Baeurle SA, "Effect of the counterion behavior on the frictional-compressive properties of chondroitin sulfate solutions", Polymer, 50, pp.1805~1813 (2009)
- Hurst RE, "Structure, function, and pathology of proteoglycans and glycosaminoglycans in the urinary tract", World J Urol, 12, pp.3~10 (1994)
- Acquadro C, "Translating overactive bladder questionnaires in 14 languages", Urology, 67, pp.536~540 (2006)
- Tarcan T, "OAB-V8 overactive bladder questionnaire validation study", Urology Bull, 21, pp.113~116 (2012)
- 오승준, "Psychometric Properties of the Korean Version of the Overactive Bladder Questionnaire (OAB-q) in a Korean Population", International Neurourology Journal, 16(2), pp.77~85 (2012), 대한배뇨장애요실금학회[DOI]
- Mostwin JL, "Pathophysiology: the varieties of bladder overactivity", Urology, 60(5 Suppl 1), pp.22~26 (2002)
- Gormley EA, "Diagnosis and treatment of overactive bladder (non-neurogenic) in adults: AUA", SUFU guideline, 2012, pp.188(6 Suppl), 2455~2463
- Brinkmann OA, "The pathogenesis of interstitial cystitis- -many hypotheses, but etiology remains uncertain", Urologe A, 39, pp.520~526 (2000)
- Wilkins EG, "Interstitial cystitis and the urethral syndrome: a possible answer", Br J Urol, 64, pp.39~44 (1989)
- Gauruder-Burmester A, "Treatment of overactive bladder with sodium chondroitin sulphate", Zentralbl Gynakol, 128, pp.336~340 (2006)
- Gauruder-Burmester A, "Follow-up at 24 months after treatment of overactive bladder with 0.2% sodium chondroitin sulfate", Aktuelle Urol, 40, pp.355~359 (2009)